COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
FDA Feedback Supports Extension Phase for Jaguar Health's Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)
Napo Pharmaceuticals plans single-blind extension phase for crofelemer trial in pediatric MVID patients, aiming to reduce parenteral support and improve clinical benefit. FDA supports protocol amendment -
-
-
COMMUNIQUÉ DE PRESSE
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression
Magdalena Biosciences initiates preclinical study on whole leaf coca extract for appetite suppression post-GLP-1 weight loss. Study conducted in Alberta, Canada -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts
Jaguar Health, Inc. to present virtually at Life Sciences Investor Forum on March 12, 2026. More about Jaguar's novel prescription drugs for gastrointestinal diseases
